Development of recombinant hirudin as a therapeutic anticoagulant and antithrombotic agent: some objective considerations.
Walenga
J M
JM
Department of Thoracic and Cardiovascular Surgery, Loyola University Medical Center, Maywood, Illinois 60153.
Pifarre
R
R
Hoppensteadt
D A
DA
Fareed
J
J
D000818:Animals; D001777:Blood Coagulation / Q000187:drug effects; D001780:Blood Coagulation Tests; D006470:Hemorrhage / Q000139:chemically induced; D024764:Hirudin Therapy; D006629:Hirudins / Q000493:pharmacokinetics / Q000494:pharmacology / Q000633:toxicity; D011994:Recombinant Proteins / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D013917:Thrombin / Q000037:antagonists & inhibitors; D013927:Thrombosis / Q000517:prevention & control*
D006629:Hirudins; D011994:Recombinant Proteins; D013917:Thrombin